Patents by Inventor Sujit K. Basu
Sujit K. Basu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220133708Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.Type: ApplicationFiled: July 6, 2021Publication date: May 5, 2022Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina Elbert
-
Publication number: 20210369958Abstract: A medicinal fluid pooling device may be used to pool multiple containers of medicinal fluid to facilitate administration of the medicinal fluid to a patient. A medicinal pooling device may include spikes covered by spike sheaths which are pierced when a container of medicinal fluid is inserted into the medicinal pooling device. The medicinal pooling device may also include a cover configured to cover the spikes. The medicinal pooling device may also include a fluidic interface which may be used to fluidly connect the medicinal pooling device to an infusion pump or syringe.Type: ApplicationFiled: September 24, 2019Publication date: December 2, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Seth Dale Jones, Madeleine Clare Gibson, Daniel Edward Roush, Dhairya Kiritkumar Mehta, Sujit K. Basu, Jennifer Craig Cordova
-
Publication number: 20210353854Abstract: An infusion pump which may include a control unit and a pump engine may be used to facilitate administration of medicinal fluids to a patient. A control unit may include a motor, a controller, a housing, and a motor coupling, where the motor coupling includes two protruding motor coupling tabs extending in a direction parallel to an output shaft of the motor. A pump engine may include a housing, a rotor disposed in the housing, and a pump coupling, where the pump coupling includes at least two protruding pump coupling tabs extending in a direction parallel to an input shaft of the rotor. The controller may be configured to change an operational mode of the infusion pump, where when the infusion pump is in a positioning mode, the controller activates the motor to move the output shaft to a predetermined angular position.Type: ApplicationFiled: September 24, 2019Publication date: November 18, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Andrew Scott Argersinger, Daniel Edward Roush, Tejas Jayendra Dhyani, Adam Blake Hartman, Brent Whitfield Byers, Angela Teresa Muriset, Kimberly Duff, Dhairya Kiritkumar Mehta, Sujit K. Basu, Jennifer Craig Cordova
-
Publication number: 20160317522Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.Type: ApplicationFiled: March 29, 2016Publication date: November 3, 2016Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina Elbert
-
Publication number: 20120088724Abstract: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.Type: ApplicationFiled: October 10, 2011Publication date: April 12, 2012Applicant: Althea Technologies, Inc.Inventors: Wen-Li Chung, Lawrence Bush, Sergey Pechenov, Sujit K. Basu
-
Patent number: 8071544Abstract: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.Type: GrantFiled: December 13, 2007Date of Patent: December 6, 2011Assignee: Althea Technologies, Inc.Inventors: Wen-Li Chung, Lawrence Bush, Sergey Pechenov, Sujit K. Basu
-
Publication number: 20110123574Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.Type: ApplicationFiled: October 19, 2010Publication date: May 26, 2011Applicant: Alkermes, Inc.Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina J. Elbert
-
Publication number: 20110111056Abstract: This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA)-peptide conjugates.Type: ApplicationFiled: June 3, 2010Publication date: May 12, 2011Applicant: Dicerna Pharmaceuticals, Inc.Inventors: Sujit K. Basu, Bob D. Brown
-
Publication number: 20110059187Abstract: This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA)-peptide conjugates.Type: ApplicationFiled: June 3, 2010Publication date: March 10, 2011Applicant: Dicerna Pharmaceuticals, Inc.Inventors: Sujit K. Basu, Bob D. Brown
-
Publication number: 20100216705Abstract: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.Type: ApplicationFiled: December 13, 2007Publication date: August 26, 2010Inventors: Wen-Li Chung, Lawrence Bush, Sergey Pechenov, Sujit K. Basu
-
Patent number: 7754242Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.Type: GrantFiled: March 19, 2003Date of Patent: July 13, 2010Assignee: Alkermes, Inc.Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina J. Elbert
-
Publication number: 20080039366Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: ApplicationFiled: May 18, 2006Publication date: February 14, 2008Applicant: Advanced Inhalation ResearchInventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Patent number: 7048908Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: GrantFiled: July 23, 2002Date of Patent: May 23, 2006Assignee: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Publication number: 20040042970Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.Type: ApplicationFiled: March 19, 2003Publication date: March 4, 2004Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina J. Elbert
-
Publication number: 20040018243Abstract: Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release of the drug can be obtained by forming particles which have a high matrix transition temperature, while fast release can be obtained by forming particles which have a low matrix transition temperature. Preferred particles include one or more phospholipids.Type: ApplicationFiled: April 28, 2003Publication date: January 29, 2004Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Jeffrey S. Hrkach, Giovanni Caponetti, Michael M. Lipp, Katharina Elbert, Wen-I Li
-
Publication number: 20030232019Abstract: The present invention is based, in part, on the unexpected discovery that aerosol particle formulations for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising an asymmetric phospholipid exhibit sustained release and/or sustained action of the agent. In some embodiments, as an alternative to one or more asymmetric phospholipids or in addition to one or more asymmetric phospholipids, the instant particles comprise one or more glycerol fatty acid esters. The present invention is directed to spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent and methods for delivery of said particles to the pulmonary system, the particles comprising a therapeutic, prophylactic or diagnostic agent and an asymmetric phospholipid and/or one or more glycerol fatty acid esters. In one embodiment, the particles comprise a combination of phospholipids wherein at least one of the phospholipids is an asymmetric phospholipid.Type: ApplicationFiled: February 20, 2003Publication date: December 18, 2003Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Katharina Elbert, Jeffrey Hrkach, Giovanni Caponetti
-
Publication number: 20030118513Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: ApplicationFiled: July 23, 2002Publication date: June 26, 2003Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Publication number: 20010036481Abstract: Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.Type: ApplicationFiled: February 23, 2001Publication date: November 1, 2001Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Giovanni Caponetti, Daniel R. Deaver, Katharina J. Elbert, Jeffrey S. Hrkach, Michael M. Lipp